BioCentury
ARTICLE | Clinical News

Eliglustat tartrate: Additional Phase III data

February 25, 2013 8:00 AM UTC

Sanofi's Genzyme Corp. unit reported additional data from the open-label, international Phase III ENCORE trial in 160 Type I Gaucher's disease patients who have been stabilized on enzyme replacement therapy evaluating twice-daily oral eliglustat tartrate compared to bi-weekly infusions of Cerezyme imiglucerase. On the secondary endpoints, the proportion of patients receiving eliglustat tartrate who met each individual component of the composite primary endpoint at week 52 was 94% for spleen volume criteria, 95% for hemoglobin level criteria, 93% for platelet level criteria and 96% for liver volume criteria. Additionally, eliglustat tartrate was non-inferior to Cerezyme in reducing mean spleen volume from baseline (6% vs. 3%). Data were presented at the Lysosomal Disease Network World Symposium in Orlando. ...